Sunitinib (Sutent™)

Last Updated: 02/27/17

Status: Currently a NF2 Clinical Trial

Index

  1. Basic Information
  2. NF2 Related Trials
  3. Treatment Information
    • Treatment Expectations
    • Concerns
    • Side Effects
  4. Other Uses
    • Treatment For
    • Patents

Sunitinib is an oral pill that is in trials for NF2, with expectations of the reduction in size of Meningiomas.

Side effects have been found to be minimal and any severe issues disappear with dose reduction, break in treatment or other treatment.

This is a new NF2 treatment and facts collected are based on use of Sunitinib for other treatments. Sunitinib has been found more effective in situations where Sorafenib (Nexavar), Temsirolimus (Torisel), Interleukin-2 (Proleukin), Everolimus (Afinitor), Bevacizumab (Avastin) and Aldesleukin helped, but they only had minimal effect.


1. Basic Information

Trade Name Sutent™
Other Names Sutent, SU-11248, sunitinibum, Sunitinib (INN), Su-011248, SU11248, SU 11248, CHEBI:38940, Sunitinib (free base), Sunitinib Malate
Pharmaceutical Company Pfizer
Prescription Information DailyMed
Treatment By Pill - Oral
Tumor Target Intracranial Meningioma
Interactions Avoid Grapefruit and Green Tea
Expectation Size reduction of Meningiomas Multi-targeted Receptor Tyrosine Kinase (RTK) Inhibitor
Inhibits VEGF-R2 and PDGF-Rbeta tyrosine kinase; has antineoplastic activity; structure in first source
Molecular Formula C22H27FN4O2
IUPAC N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
ChemSpider 4486264 (accessed 16:29, Oct 11, 2012)
PubChem CID 5329102

2. NF2 Related Trials

Available Through: Memorial Sloan-Kettering Cancer Center


1. Trial Name Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma
ClinicalTrials.gov NCT00561665 Status Unknown
Condition Brain and CNS Tumors Phase Phase 2
Collaborator National Cancer Institute (NCI) Sponsor Memorial Sloan-Kettering Cancer Center

2. Trial Name Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
ClinicalTrials.gov NCT00589784 Status Ongoing
Condition Meningioma Phase Phase 2
Sponsors and Collaborators Dana-Farber Cancer Institute, University of Virginia, University of Pittsburgh and Pfizer Principal Investigator Memorial Sloan-Kettering Cancer Center, New York

3. Treatment Information

Sunitinib is Chemically similar to Imatinib. Imatinib has been used to treat other conditions that did not generally respond to standard chemotherapy or radiation, but while some people did not respond to it, 50% developed a resistance to its effects within 2 years. For those conditions, Sunitinib was started after Imatinib resistance was developed till conclusion was that Sunitinib was simply a more effective treatment. Sunitinib reduced the relative risk of disease progression or death by a considerable percentage.

Treatment Expectations

Size reduction of Meningiomas.

Precautions

  • Tell your doctor and pharmacist if you are allergic to Imatinib, mannitol, or any other medications.
  • Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins and nutritional supplements you are taking or plan to take
  • Tell your doctor and pharmacist what herbal products you are taking, especially St. John's wort. Your doctor will probably tell you not to take St. John's Wort while taking Sunitinib.
  • Tell your doctor if you have or have ever had a bleeding problem; angina (chest pain); a slow, fast, or irregular heartbeat; a heart attack; heart bypass surgery; heart failure; high blood pressure; pulmonary embolism (PE; blood clot in the lungs); seizures; a stroke or transient ischemic attack (TIA, mini-stroke); or heart, kidney, liver, or thyroid disease.
  • Tell your doctor if you are pregnant, could be pregnant, or plan to become pregnant. You should not become pregnant while you are taking sunitinib.
  • Tell your doctor if you are breast-feeding. You should not breast-feed while you are taking sunitinib.
  • If you are having surgery, including dental surgery, tell the doctor or dentist that you are taking sunitinib.
  • Sunitinib may cause your skin to turn yellow and your hair to lighten and lose color. This is probably caused by the yellow color of the medication and is not harmful or painful. Your natural skin and hair color will likely return after you stop taking sunitinib.
  • Sunitinib may cause high blood pressure. Your blood pressure should be checked regularly while you are taking sunitinib.
  • Do not eat grapefruit, drink grapefruit juice or green tea while taking this medication.

4. Side Effects

Major side effects are uncommon. Since people with NF2 are taking these medications at a low dose, only minimal side effects would likly happen. However, long term use is primarily where these major side effects take place. Monthly Blood and Urine Tests can usually point to an issue before any issues are a real problem. Talk to your doctor.

Immediately Contact Doctor if you start to experience:
  • Black And Tarry Stools
  • Bloody Vomit
  • Chest Pain
  • Chills
  • Coughing Up Pink Or Bloody Mucus
  • Difficulty Falling Asleep Or Staying Asleep
  • Fever
  • Increased Urination, Especially At Night
  • Rapid, Irregular, or Pounding Heartbeat
  • Red Blood In Stools
  • Shortness Of Breath
  • Stomach Pain Or Swelling
  • Sudden Severe Back, Stomach, or Leg Pain
  • Swelling Of The Feet Or Ankles
  • Swelling, Tenderness, Warmth, or Redness Of A Leg
  • Unusual Bruising Or Bleeding
  • Vomit That Looks Like Coffee Grounds
  • Weight Gain
Additional Possible Side Effects:
  • Change In The Way Things Taste
  • Constipation
  • Depression
  • Diarrhea, Gas
  • Dry Mouth, Pain, Irritation, or Burning Sensation of The Lips, Tongue, Mouth or Throat
  • Dryness, Thickness, Cracking, Or Blistering Of Skin On The Palms Of The Hands And The Soles Of The Feet
  • Extreme Tiredness
  • Hair Loss
  • Heartburn
  • Loss Of Appetite
  • Muscle Or Limb Pain
  • Nausea, Vomiting
  • Pain, Burning, Numbness, Or Tingling In The Hands Or Feet
  • Rash
  • Slow Speech
  • Thin, Brittle Fingernails Or Hair
  • Unusual Discomfort In Cold Temperatures
  • Weakness
  • Weight Loss
  • White Patches, Sores On The Lips, or In The Mouth And Throat

5. Other Uses Patents

Treatment for

  • Gastrointestinal Stomach Tumors - GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach, in people with tumors that were not treated successfully with Imatinib (Gleevec) or people who cannot take Imatinib.
  • Advanced Renal Cell Carcinoma (RCC) - a type of Cancer that begins in the cells of the kidneys).

Patents

Top 5 of 101 Treatments
Patent # Date Title
US20090118240A1 07-02-2012 LOCAL TREATMENT OF NEUROFIBROMAS LOCAL TREATMENT OF NEUROFIBROMAS
US20090318525A1 04-09-2012 Process For Preparing A 3-Pyrrole Substituted 2-Indolinone Malate Salt Process For Preparing A 3-Pyrrole Substituted 2-Indolinone Malate Salt
US20100143946A1 04-02-2012 ALPHA-SYNUCLEIN KINASE ALPHA-SYNUCLEIN KINASE
US20120029046A1 02-01-2012 CRYSTALLINE FORM OF SUNITINIB AND PROCESSES FOR ITS PREPARATION
US20110306647A1 12-14-2011 NOVEL POLYMORPHS OF SUNITINIB MALATE


What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017